Browsing Tag
Actuate Therapeutics
3 posts
Could oral elraglusib emerge as a combination backbone for RAS-targeted cancer therapies?
Actuate Therapeutics, Inc. is advancing oral elraglusib to target resistance biology in cancer. Discover what this means for oncology markets.
Is elraglusib emerging as a new frontline option in metastatic PDAC?
Read how Actuate Therapeutics’ elraglusib Phase 2 survival data could reshape metastatic PDAC treatment and investor expectations.
How elraglusib’s long-term Phase 2 survival data positions Actuate Therapeutics in a difficult pancreatic cancer market
Find out how elraglusib’s long-term Phase 2 survival data is positioning Actuate Therapeutics in the challenging metastatic pancreatic cancer market.